Form 4: KalVista Pharmaceuticals Executive Christopher Yea Reports Stock Transactions

Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.

Summary

• Christopher Yea, the Chief Development Officer of KalVista Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On February 17, 2025, Yea acquired 4,204 shares of common stock and disposed of restricted stock units (RSUs) and performance stock units (PSUs).
• On February 18, 2025, Yea sold 2,601 shares of common stock at a price of $9.8242 per share.
• These transactions resulted in Yea owning 92,745 shares of common stock following the reported transactions.
• The sale of shares was to cover tax withholding obligations related to the vesting and settlement of RSUs and PSUs and was not a discretionary transaction.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock transactions related to compensation and tax obligations, without indicating any strategic shift or concern.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and actions regarding their company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a company officer.
• Employees holding similar stock-based compensation may be interested in the details of the transactions.

Key Dates

Keywords

Form 4, KalVista Pharmaceuticals, Christopher Yea, stock transaction, beneficial ownership, RSU, PSU, tax withholding